PatentJun 16, 2026, 08:16 AM
Cingulate Secures U.S. Patent for ADHD Drug CTx-1301 Until 2042
AI Summary
Cingulate Inc. announced the issuance of U.S. Patent No. 12,653,791 by the USPTO for its lead ADHD asset, CTx-1301. This patent covers key aspects of CTx-1301's formulation and method of use, extending exclusivity through December 2042. This marks the company's first wholly-owned U.S. patent for CTx-1301, significantly strengthening its intellectual property portfolio and supporting its path toward potential commercialization.
Key Highlights
- Cingulate Inc. announced the issuance of U.S. Patent No. 12,653,791 by the USPTO for its lead ADHD asset, CTx-1301.
- The patent covers key aspects of CTx-1301's formulation and method of use.
- Exclusivity for CTx-1301 is extended through December 2042.
- This marks the company's first wholly-owned U.S. patent for CTx-1301.
- The patent strengthens Cingulate's intellectual property portfolio for its Precision Timed Release™ platform.
- Cingulate also holds patents in 30 European territories, Australia, Canada, and Israel.
Price Impact
More from CING